SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly results are the dominant focus, with traders watching whether U.S. commercial growth and forward guidance can exceed already-high expectations. The community is split between optimism about AI-driven growth and concern that the stocks rich valuation and broader AI-sector weakness could prompt a selloff even if results beat estimates.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp pre-earnings selloff, following Intels weak results and broader chip-sector weakness, has traders debating whether the concerns point to wider industry problems or are specific to Intel. Bulls see the pullback as overdone and expect AMDs growth story to hold up, while bears cite its high valuation and the risk of disappointing guidance.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp, volatile market pullback is driving discussion, with traders focused on weakness in AI and technology stocks, midterm-election uncertainty, and geopolitical risk around Iran. Many expect further downside, while others see a possible rebound and are watching Apples earnings as a test of market sentiment.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings report, the first under CEO John Ternus, is the dominant focus, with traders watching holiday-quarter guidance, iPhone demand and rising memory costs. The community is split between expectations of a beat and a rally and concerns that stretched valuation, margin pressure or weak guidance could trigger a selloffand weigh on the broader market.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells announced all-stock acquisition of Lumentum has driven attention as shares sell off, with traders worried about dilution, the deals size and the long path to closing. Some see the combination of Marvells connectivity chips and Lumentums optical technology as a strategic bet on AI data-center demand, while others question its cost and execution risks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a tech-led selloff, with traders debating whether AI-linked selling is a temporary correction or a deeper unwind as heavy investment faces scrutiny over returns. Some see oversold conditions as a buying opportunity, while others expect more downside; election and earnings uncertainty are adding to volatility.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reached its prespecified 80th death event, triggering final analysis and anticipation of GPS topline results; the milestone was followed by a sharp selloff. Traders disagree over whether the decline reflects profit-taking and binary-trial risk or suspected manipulation or an information leak, with no results yet establishing the trials outcome.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum has driven a sharp selloff, as traders focus on the fixed share exchange ratio, dilution concerns and the long wait before closing, which leaves LITEs value exposed to MRVLs share price rather than guaranteeing the headline premium. The community is split between buyers viewing the discount and AI-optics strategy as an opportunity and shareholders criticizing the terms or speculating the deal could fail.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp selloff in semiconductor and tech shares, with traders debating whether AI-related valuations and spending are due for a deeper correction or whether the drop is a buying opportunity. The funds 3x leverage is amplifying the volatility, while election and Iran-related uncertainty add to the risk-off mood.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp selloff in semiconductor and AI-linked stocks is driving discussion, with traders citing doubts about AI spending returns, weak company guidance and broken technical support. The community is divided between seeing a deeper AI-trade correction and treating the decline as a buying opportunity because chip demand remains strong.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 14.59% on an annualized basis producing an average annual return of 26.37%. Currently, Cogent Biosciences has a market capitalizationread more...

$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 16.44% on an annualized basis producing an average annual return of 28.63%. Currently, Cogent Biosciences has a market capitalizationread more...

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an annualized basis producing an average annual return of 30.55%. Currently, Cogent Biosciences has a market capitalizationread more...

$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an annualized basis producing an average annual return of 33.55%. Currently, Cogent Biosciences has a market capitalizationread more...

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an annualized basis producing an average annual return of 40.76%. Currently, Cogent Biosciences has a market capitalizationread more...

Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?

Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now...

Lilly’s Phase 3 Breakthrough Ignites Race for the Next Cancer Stock Breakout

Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. $LLY, $NTHI, $COGT, $OLMA, $BMY, $PFE

RSI Alert: Cogent Biosciences (COGT) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Cogent Biosciences (NASDAQ:COGT) Releases Earnings Results

Cogent Biosciences (NASDAQ:COGT - Get Free Report) released its quarterly earnings data on Tuesday. The technology company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates...

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Cogent Biosciences Inc

Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges

Equity

Bullish Sentiment

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced systemic mastocytosis (NonAdvSM).The Summit Part 2 trial met its primary endpoint with a statistically significant placebo-adjusted improvement of 8.91 points in total symptom score (TSS) at 24 weeks.&nbsp;Patients treated with bezuclastinib saw a mean TSS reduction of 24.3 points, compared to 15.4 points for placebo.&nbsp;The drug also met all key secondary endpoints, including reductions in serum tryptase, with 87.4% of treated patients achieving at least a 50% drop versus none in the control group.&nbsp;Most adverse events were low-grade. Discontinuations due to side effects occurred in 5.9% of patients, all of whom recovered.H.C. Wainwright raised its price target to $22 from $12 and maintained a 'Buy' rating, raising its approval probability estimate to 95% from 60%, calling bezuclastinib a potential new standard of care.&nbsp;Jefferies lifted its target to $28 from $23 with a 'Buy' rating, citing a “home run” outcome and a $1 billion market opportunity in ISM alone.Leerink increased its target to $18 from $16 and reiterated an 'Outperform' rating, noting the safety profile exceeded expectations and pointing to strong positioning ahead of the Peak and Apex trial readouts due later in 2025.&nbsp;Baird took a more conservative view, raising its target to $9 from $7 while maintaining a 'Neutral' rating, stating that the results were better than the worst-case scenario but fell short of the best.Cogent remains on track to submit a new drug application (NDA) for bezuclastinib by year-end 2025 and will present detailed Summit findings at a medical conference later this year.Separately, Cogent announced a proposed public offering of $150 million in common stock.&nbsp;The company said proceeds will support continued development, regulatory and commercial preparation for bezuclastinib and other pipeline candidates, as well as general corporate purposes.&nbsp;On Stocktwits, retail sentiment for Cogent was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/COGT">Cogent’s stock</a> has risen 25.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple firms raised their price targets on Cogent Biosciences (COGT) following strong results from the Phase 3 Summit trial of bezuclastinib/Photo credit: Getty Images

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Feed

News

Sentiment

Earnings

Fundamentals

Info

COGT News